Sotera Health Company SHC

Broyhill Asset Management, a Charlotte-based firm, issued its second-quarter 2026 investor letter, which is available for download here. The Broyhill Equity Composite gained 8.8% in Q2, trailing the MSCI All Country World Index’s 15.1% and the MSCI ACWI Value Index’s 10.8%. For the first half, the Composite returned 2.3%, versus 11.5% for the Index. The […]

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the research tools & consumables industry, including Sotera Health Company (NASDAQ:SHC) and its peers.

Sotera Health Company trades at $19.02 per share and has stayed right on track with the overall market, gaining 11.3% over the last six months. At the same time, the S&P 500 has returned 13.1%.

Sotera Health’s second quarter was marked by broad-based growth across its business units, which drove a positive market reaction. Management credited robust demand in both core sterilization (Sterigenics) and isotope supply (Nordion), coupled with improved customer engagement at Nelson Labs, for the outperformance. CEO Alton Shader highlighted that "Sterigenics built on strong momentum from Q1, delivering 7% constant currency revenue growth," while Nordion benefited from favorable Cobalt-60 shi

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over the past six months, beating the S&P 500 by 11.2 percentage points.

US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index’s 23% return. A copy of the letter can be downloaded here. The second quarter results were a complete reversal of Q1 results, with the portfolio appreciating 23.0% (gross) and 23.3% (net), […]

Healthcare services company Sotera Health (NASDAQ:SHC) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.2% year on year to $321.4 million. The company expects the full year’s revenue to be around $1.25 billion, close to analysts’ estimates. Its non-GAAP profit of $0.26 per share was 8.7% above analysts’ consensus estimates.

Sotera Health Company’s Q2 2026 results, released on August 6, showed revenue rising to US$321.38 million and net income to US$53.64 million, with earnings per share from continuing operations increasing to US$0.19 from US$0.03 a year earlier. Management’s decision to raise full-year guidance after broad-based growth across Sterigenics, Nordion and Nelson Labs highlights improving profitability supported by pricing, volume mix and operational execution. We’ll now examine how Sotera Health’s...

Moby summary of Sotera Health Company's Q2 2026 earnings call

Healthcare services company Sotera Health (NASDAQ:SHC) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.2% year on year to $321.4 million. The company expects the full year’s revenue to be around $1.25 billion, close to analysts’ estimates. Its non-GAAP profit of $0.26 per share was 8.7% above analysts’ consensus estimates.

Q2 2026 net revenues increased 9.2% or 8.0% on a constant currency basis(1) compared to Q2 2025Q2 2026 net income of $54 million or $0.19 per diluted share, compared to net income of $8 million or $0.03 per diluted share in Q2 2025Q2 2026 Adjusted EBITDA(1) increased 10.0%, or 8.7% on a constant currency basisQ2 2026 Adjusted EPS(1) of $0.26, an increase of 30% per diluted shareCompany raises both full-year 2026 net revenues growth outlook to 5.25% - 6.75% and Adjusted EBITDA growth outlook to 5